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Rationale: Analogous to the adenoma-carcinoma sequence in the
colon, it has been proposed that adenocarcinoma (AC) in the lung
arises fromadenomatous hyperplasia that progresses through atyp-
ical adenomatous hyperplasia to AC. However, the data supporting
this sequence are largely circumstantial and the almost impossible
task of identifying these lesions before resection rules out any longi-
tudinal study in humans.
Objectives, Methods, and Results: We show in mice that the loss of
function of the neurokinin-1 receptor (NK-1R)—due to either a
pharmacologic or genetic manipulation—results in a sequence of
morphologic changes in response to bleomycin treatment that pre-
cede the development of AC. We also demonstrate that a series of
alterations in gene expression of proliferation markers (i.e., PCNA
and Ki-67) and cell cycle regulators (i.e., FHIT, p53, and p21) charac-
terizes the sequence of the precursor lesions. The loss of function
of the NK-1R results in changes of the apoptotic rate and in a
delay of DNA break recovery of alveolar epithelial cells following
bleomycin treatment. TheNK-1Rblockade interfereswith a caspase-
independent pathway of apoptosis by affecting both the transloca-
tion of Nur77 into the cytoplasm and the expression of some impor-
tant Bcl2 family members such as Bcl2 and Bak.
Conclusions:Toour knowledge, this is the firstmodel todemonstrate
a role for NK-1R in lung epithelial cell death and tumorigenesis.
This animal model may provide new information on the biology of
AC and will facilitate designing and testing of new therapeutic
interventions.
Keywords: adenocarcinoma; bleomycin; cell cycle regulators; cell
death; proliferation markers
Thepulmonary fibrosis in rodents caused by intratracheal admin-
istration of a single dose of bleomycin (BLM) is widely used as
amodel to study themechanisms of fibrotic lung diseases. Recent
evidence has suggested the involvement of tachykinins, and in
particular of substance P (SP), in pulmonary fibrosis (1, 2). High
levels of immunoreactive SP have been found in bronchoalveolar
lavages of patientswith idiopathic pulmonary fibrosis and pulmo-
nary sarcoidosis (2). It has been demonstrated that the neuropep-
tide SP is a potent effector of fibroblast migration and prolifera-
tion (3), which in conjunction with other factors (e.g., cytokines,
reactive oxygen species) could worsen and accelerate the devel-
opment of lung fibrosis. In particular, a neuropeptide regulation
of proinflammatory and fibrogenic cytokine responses has been
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postulated and evidence has been reported demonstrating that
SP can induce expression of tumor necrosis factor (TNF)- (4,
5) and interleukin (IL)-1 (6), two important mediators that can
be found at an early stage after BLM treatment. SP released
from sensory nerve terminals greatly contributes to neurogenic
inflammation mainly by the activation of neurokinin-1 receptors
(NK-1R) (7), which are widely expressed in lungs in several cell
types including endothelial, epithelial, and smooth muscle cells,
monocytes, macrophages, neutrophils, fibroblasts, and mast cells
(8–10). NK-1R has recently been shown to be involved in an
alternative, programmed cell death (11).
Originally, the aim of the present study was the evaluation
of the role of NK-1R in the lung fibrogenic response to BLM in
mice treated with a selectiveNK-1R antagonist. NK-1Rblockade
did not affect the fibrotic response (either in the fibrosis-prone
C57 Bl/6J or in the fibrosis-resistant Balb/c mice: see Figure E1
in the online supplement); however, it resulted in the develop-
ment of solitary or multiple foci of lung cancer classified as
adenocarcinoma (AC) (12) at 21 d after BLM. This finding was
unexpected.
To elucidate the specific role of NK-1R signaling in lung
tumorigenesis, we used NK-1R knockout (NK1r/) mice gener-
ated on both C57 Bl/6J and Balb/c backgrounds. This enabled
us to observe that (1) the loss of function of the NK-1R results
in changes of the apoptotic rate and expression of mediators
involved in cell death in response to DNA strand breaks induced
by BLM, (2) a sequence of precursor lesions precedes the devel-
opment of AC, and (3) a series of alterations in gene expression
characterizes the precursor lesions, which precede the develop-
ment of AC.
The almost impossible task of identifying these precursor
lesions before resection rules out any longitudinal study in hu-
mans. By studying NK1r/ mice at various times after BLM
administration, we were able to demonstrate that AC arises
from adenomatous hyperplasia (AH), which progresses through
atypical AH (AAH) to AC. The main characteristics of the
tumor we report here (i.e., cell of origin, timing of development,
morphology of precursor lesions, and histologic and molecular
aspects) are quite different from those induced inmice by several
carcinogens (13) or by genetic manipulation (i.e., K-Ras condi-
tional mutation) (14–16).
To our knowledge, this is the first model to demonstrate a role
for NK-1R in alveolar epithelial cell death and tumorigenesis.
Despite the fact that several studies using gene expression profil-
ing have been performed to identify mechanisms of tumor biol-
ogy in human lung (17–19), a role for NK-1R has not been put
forward.
Some of the results of these studies have been previously
reported in the form of abstracts (20–22).
METHODS
Animals
Balb/c and C57 Bl/6J mice were supplied by Charles River Italia (Calco,
Italy). NK-1R knockout mice (NK1r–/–) were developed by one of us
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(N.P.G.) at Harvard University, Boston, Massachusetts, as previously
described in detail (23) and back-crossed both to Balb/c and C57 Bl/6J
mice. The animals were bred at the University of Siena, Siena, Italy.
The mice were housed in a light (07:00 to 19:00) and temperature
controlled (18 to 22C) environment, and food (Global Diet 2018;
Mucedola, Settimo Milanese, Italy) and water were provided for con-
sumption ad libitum. All animal experiments were conducted in confor-
mance with the Guiding Principles for Research Involving Animals and
Human Beings and approved by the local ethical committee of the
University of Siena, Siena, Italy.
Animal Treatments
Asingle dose of 150g of BLM(EuroNipponKayakuGMB, Frankfurt/
Main, Germany) in 50 l saline solution was intratracheally adminis-
tered to 8- to 16-wk-old male mice of the different strains. All intratra-
cheal instillations were performed under ether anesthesia. Primarily,
we evaluated the role of NK-1R in the lung response to BLM in groups
of 18 animals for each strain treated with L-733,060 (Merck, Darmstadt,
Germany), a selective NK-1R antagonist. It was dissolved in sterile
water at a concentration of 16.6 g/l and continuously delivered at a
rate of 8.3 g/h for 2 wk by osmotic pumps (Alzet 2002; Alza Corpora-
tion, Palo Alto, CA). The pumps were implanted subcutaneously ac-
cording to the manufacturer’s instructions 24 h before BLM treatment.
Animals receiving either 50 l saline or L-733,060 alone served as
controls.
Twenty-one days later, the animals from all groups were injected
with an overdose of pentobarbital sodium and killed by cutting the
abdominal aorta. The lungs were then excised and processed for histo-
logic examination. The evaluation of the fibrotic response was per-
formed bymorphometric and biochemical analyses (see legend to Figure
E1).
Mouse Tumor Analysis
This study was performed using NK1r/ mice (8 to 16 wk of age)
developed on both C57 and Balb/c backgrounds. These animals were
used for studying themorphology and the alterations in gene expression
characterizing the sequence of precursor lesions that precede AC
development.
At 0, 1, 3, 5, 7, 14, 21, and 28 d after BLM treatment, the NK1r/
mice developed on both C57 and Balb/c backgrounds were killed and
the lungs were excised. For conventional light microscopy and immuno-
histochemistry, lungs were fixed intratracheally with buffered formalin
(5%) at a constant pressure of 20 cm H2O at least for 24 h, dehydrated,
cleared in toluene, and embedded in paraffin. Immunohistochemistry
was performed using antibodies against Clara cell secretory protein
(CCSP), pro–surfactant protein-C, fragile histidine triad (FHIT), prolif-
eration cell nuclear antigen (PCNA), p53, p21, Ki-67, Nur77, and active
caspase 3. Samples were also analyzed by terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick-end labeling (TUNEL) tech-
nology using the in situ Cell Death Detection Kit, Fluorescein (Roche
Diagnostics, Basel, Switzerland), according to the manufacturer’s rec-
ommendations. For biochemistry and RNase protection assay (RPA)
analysis, lung samples were processed according to standard procedures.
Western blotting was used to analyze activated caspase 3. RPA was
performed using multiprobe template sets for analyzing mRNAs for
BclW, Bfl1, BcLXL, BclXS, Bak, Bax, Bcl2, Bad, and caspases 3, 7,
and 8. The distribution of staining was semiquantitatively scored based
on the percentage of positive cells: 0,  5%; 1, 6–25% stain positive;
2, 26–50% stain positive; 3, 51–75% stain positive; and 4, 76–100%
stain positive. The TUNEL labeling index (LI) was scored by determin-
ing the average count of the number of cells with positively staining
nuclei in airways and epithelial cells. Immunohistochemical examina-
tion and TUNEL LI were performed in a blinded fashion by two
observers (additional details on the methods and reagents for making
these measurements are provided in the online supplement).
Statistical Analysis
For each parameter, either measured or calculated, the values for indi-
vidual mice were averaged and the SD was calculated. The significance
of the differences between groups was calculated using one-way analysis
of variance (F-test). A p value of less than 0.05 was considered
significant.
RESULTS
Pharmacologic Blockade of NK-1R Leads to AC Development
after BLM Treatment
All the animals (24 mice; 100% incidence) treated with the
selective NK-1R antagonist showed multiple foci of AAH and
AC in the peripheral lung parenchyma at 21 d after BLM instilla-
tion (Figures 1A and 1B). In these animals, solitary or multiple
nodules of parenchymal consolidation are present in the periph-
ery of the lung. The size of these lesions ranges from less than
1 mm to about 3 mm. From a histopathologic point of view,
these lesions are characterized by foci of AAH or by well-differ-
entiated alveolar ACs, similar to well-differentiated human ACs
(24, 25), but without mucin production or desmoplasia. The
foci of AAH are characterized by groups of alveoli distributed
around terminal bronchioles, which are well demarcated by plur-
istratified, plump, cuboidal or low columnar cells with the mor-
phology of type II pneumocytes or Clara cells (Figure 1C, in
the rectangle). The parenchymal nodules show several areas of
frankAC (Figure 1C), which display histologic features of malig-
nancy, such as increased cellularity, nuclear polymorphism in-
cluding enlarged nuclei with prominent nucleoli, nuclear hyp-
erchromatism, and an increased number of mitotic figures
(Figure 1D). In these areas, the tubular arrangement is often
completely destroyed due to the cell proliferation. No evidence
of stromal, vascular, or pleural invasion was found.
None of these alterations were observed in either Balb/c or
C57 Bl/6J mice untreated with the selective NK-1R antagonist
after BLM instillation.
Under gross examination, the peripheral nodules can be easily
identified on the lung surface in specimens fixed in the inflated
state (Figure 1E).
The specific role played by NK-1R in the development of
these lesions was investigated in NK1r/ mice generated on
C57 Bl/6J andBalb/c backgrounds. At 21 d after BLM treatment,
the same lesions were observed in all NK1r/ mice (18 of 18)
of the different strains (Figures 2A and 2B).
Mice carrying a targeted knockout of NK-1R do not develop
spontaneous tumors and in particular lung ACs during their life.
A Sequence of Precursor Lesions Precedes AC Development
NK1r/ mice with either C57Bl/6 or Balb/c background were
used to study the histopathologic changes that precedeACdevel-
opment as well as the alterations in gene expression that charac-
terize the sequence of these histopathologic changes.
Analogous to the adenoma–carcinoma sequence in the colon,
it has been proposed that AC arises in the lung from AH, which
progresses through AAH to AC (26). By studying NK1r/mice
at various times after BLM administration, we were able to
demonstrate this morphologic sequence in our experimental ani-
mals (Figure 3). In particular, AH foci characterized by a mono-
layer of cuboidal or low columnar cells, which line a group of
alveoli, are the predominant lesion between 7 and 14 d after
BLM administration (Figure 3B). Between 14 and 21 d after
BLM, the predominant lesion is represented by areas of AAH
that are recognized as well demarcated foci of epithelial prolifer-
ation with some cytologic atypia (Figure 3C). These areas are
characterized by a pluristratification of epithelial cells showing
enlarged nuclei and hyperchromasia. From 21 d on, the areas
of AC predominate (Figure 3D). The latter are well recognized
by the presence of columnar, peg-shaped, or cuboidal cells show-
ing an increased mitotic rate and nuclear polymorphism.
In some histologic sections, it is also possible to demonstrate
small clusters of cuboidal cells (cuboidal cell hyperplasia; Figure
3A) soon after BLM administration (between 5 and 7 d).
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Figure 1. Morphologic appear-
ance of peripheral lung tumors
in mice treated with the
neurokinin-1 receptor (NK-1R)
antagonist L-733,060 at 21 d
after treatment with bleomycin
(BLM). (A, B ) Lung peripheral
parenchyma in a C57 Bl/6
mouse (A ) and a Balb/c mouse
(B ) treated with L-733,060,
containing areas of atypical ad-
enomatous hyperplasia (AAH)
and adenocarcinoma (AC) at
21 d after BLM treatment.
Hemotoxylin–eosin (H&E) stain.
(C ) Higher magnification of
(A ). In the rectangle, note an
area of AAHwith the character-
istic pluristratification of cuboi-
dal or low columnar cells lining
alveolar spaces (arrowheads).
Some parenchymal nodules
show histologic features of
malignancy (arrows). H&E
stain. (D ) Highermagnification
of B. This area of frank AC is
characterized by high cellularity,
nuclear polymorphism including
enlarged nuclei with promi-
nent nucleoli (arrowheads),
and an increased number of
mitotic figures (arrows). H&E
stain. (E ) Gross appearance of
a peripheral nodule on the sur-
face of a lung fixed at inflated
state from a Balb/c mouse
treated with L-733,060 at 21 d
after BLM.
Alveolar Type II Is the Cell of Origin of AC in NK1r/ Mice
after BLM Treatment
Due to the presence of cell populations resembling type II pneu-
mocytes and Clara cells in the phenotypic traits of precursor
lesions (AH and AAH) that characterize the development of
ACs, an immunohistochemical approach for identification of
specific markers for these cells was used to study the histogenesis
Figure 2. Morphologic appear-
ance of peripheral lung tumors
in NK1r/ mice generated on
C57 Bl/6J and Balb/c back-
grounds at 21 d after BLM. (A )
NK1r/ mouse (C57 Bl/6J)
showing areas of AC and AAH
around a bronchiole. H&E
stain. (B ) NK1r/ mouse
(Balb/c) showing several foci of
AC in the periphery of a bron-
chiole. H&E stain.
of this tumor. In particular, immunohistochemistry was per-
formed using antibodies against CCSP and the pro– surfactant
protein C, commonly used markers that distinguish between
Clara cells (Figure 4F) and alveolar type II cells (Figure 4E),
respectively. We found that in both AH (Figure 4A) and AAH
(Figure 4B), cells stain very strongly for pro–surfactant protein
C, but are negative for CCSP (data not shown), whereas in AC
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Figure 3. Sequence of
adenomatous hyper-
plasia (AH) to AC in the
lungs of NK1r/ mice
after BLM. (A ) Small
clusters of cuboidal cells
(cuboidal cell hyperpla-
sia) in the lung paren-
chyma of an NK1r/
Balb/c mouse at 5 d
after BLM treatment. (B )
Area of AH in the lung
of an NK1r/ Balb/c
mouse at 7 d after BLM
treatment. A group of alveoli are lined by a monolayer of cuboidal or low columnar cells. (C ) AAH in the lung parenchyma of an NK1r/ Balb/
c mouse at 14 d after BLM. AAH is characterized by a pluristratification of epithelial cells showing enlarged nuclei and hyperchromasia. Scattered
inflammatory cells are present. (D ) Area of AC in the lung of an NK1r/ Balb/c mouse at 28 d after BLM treatment showing columnar, peg-
shaped, or cuboidal cells with increased mitotic rate and nuclear polymorphism. (A–C) H&E stain.
cells stain less intensely for pro–surfactant protein C (Figure
4C) and are negative for CCSP (Figure 4G). In addition, at 5
to 7 d after BLM treatment, it was possible to demonstrate a
general positivity for pro–surfactant protein C (Figure 4D) and
no expression of CCSP in small foci of cuboidal cell proliferation.
A Sequence of Alterations in Gene Expression Characterizes
the AH to AC Sequence
As mentioned above, a series of precursor lesions characterizes
the development of AC in NK1r/ mice. In particular, foci of
AH that progress through AAH to AC are evident in lung
parenchyma from 14 to 21 d after BLM treatment. This period
has been chosen to study different proliferation markers and
cell cycle regulators during the adenoma–carcinoma sequence.
In Figures 5A–5C, the immunohistochemical staining for the
tumor suppressor FHIT during the sequence is reported. The
data obtained demonstrate a progressive decreasing FHIT ex-
pression from AH to AC. On the contrary, staining for PCNA
marker (Figures 5D–5F) and Ki67 proliferation marker (Figures
5G–5I) increases during the AH to AC sequence with increasing
atypia.
Figure 4. Immunohistochemistry
of pro–surfactant protein C (pro–
SP-C) and Clara cell secretory pro-
tein (CCSP) in the morphologic le-
sions that characterize the AH to
AC sequence. (A) Strong immuno-
staining for pro–SP-C in foci of AH
(NK1r/ Balb/c mouse at 7 d after
BLM treatment). (B ) Positive im-
munostaining for pro–SP-C in epi-
thelial cells of AAH lesion (NK1r/
Balb/c mouse at 14 d after BLM
treatment). (C ) Less intense stain-
ing for pro–SP-C in AC areas
(NK1r/ Balb/c mouse at 28 d
after BLM treatment). (D ) Anti–
pro–SP-C staining in proliferating
cuboidal cells in the parenchyma
of a NK1r/ Balb/c mice at 7 d
after BLM treatment. (E ) Alveolar
type II cells with positive immunostaining for pro–SP-C in an unaffected area of lung parenchyma. (F ) Epithelial cells lining a bronchiole with
positive immunostaining for CCSP (lung from a control mouse). (G ) Positive immunoreaction for CCSP on bronchiolar epithelial cells. The adjacent
area of AC remains negative.
We also examined by immunohistochemistry the interaction
between the expression of p53 and of another member of the
p53 signaling pathway, namely p53-inducible cyclin-dependent
kinase inhibitor p21Waf1/Cip1 (p21). It is well known that p53
and p21 proteins are not usually stained in bronchiolar and
epithelial lung cells under normal conditions, but they can be
labeled in reactive lesions where a direct correlation between p53
and p21 expression is usually found (27). This correlation is lost
during the adenoma–carcinoma sequence under our experimental
conditions. In particular, the progressive accumulation of p53
protein we observe during the various progression steps of the
AH to AC sequence (Figures 5K–5M) is not matched by an
increase of p21 expression. Thus, p21 protein that is highly
labeled in AH (Figure 5N) tends to be relatively low in AAH
and absent from AC (Figures 5O and 5P). The distribution of
the expression of proliferation markers and cell cycle regulators
in the adenoma–carcinoma sequence is reported in Table 1.
Loss of Function of NK-1R Does Not Affect Initial Yield of DNA
Breaks but Influences Rate of Their Recovery
Representative pictures of DNA strand break (SB) extremities
labeling from lung sections of wild-type Balb/c mice at 3 h and
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Figure 5. Sequence of alter-
ations in gene expression dur-
ing the AH–AAH–AC sequence.
Immunohistochemical staining
for the tumor suppressor frag-
ile histidine triad (A–C), prolif-
eration cell nuclear antigen
(PCNA; D–F), Ki67 (G–I), p53
(K–M), and p21 (N–P) during
the AH to AC sequence (from
left to right). Fragile histidine
triad (FHIT) staining and p21
staining (positive cells in brown
and brown-red, respectively)
show a progressive decreasing
expression starting from AH (A,
N) to AC (C, P). PCNA (brown-
red staining), Ki67 (fluorescent
staining), and p-53 (brown
staining) show weak (D ) or no
(G, K) expression in AH. A
moderate or strong expression
of these proteins is seen in
AAH (E, H, L) and AC (F, I, M),
respectively.
1, 3, and 5 d after BLM are reported in Figures 6B, 6D, 6F, and
6H, respectively. In these animals, the fluorescein labeling is very
strong in epithelial cells of segmental bronchi and bronchioles at
3 h after BLM administration (LI: 18.5  10.1) and less evident
in parenchymal cells (LI: 4.8  2.1; Figure 6B). At 1 d after
BLM, a large number of alveolar cells are intensely stained
throughout the lung parenchyma (Figure 6D) (LI: 17.4  8.5)
when a marked decrease in the labeling of airway epithelial cells
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TABLE 1. DISTRIBUTION OF THE EXPRESSION OF




0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
FHIT n 0 0 8 16 18 6 23 1
% 33 66 75 25 96 4
PCNA n 2 22 17 7 10 14
% 8 92 71 29 42 58
Ki67 n 24 14 10 20 4
% 100 58 42 83 17
p53 n 24 11 13 10 14
% 100 46 54 42 58
p21 n 15 9 11 13 19 5
% 63 37 46 54 79 21
Definition of abbreviations: AAH 	 atypical adenomatous hyperplasia; AC 	
adenocarcinoma; AH 	 adenomatous hyperplasia; FHIT 	 fragile histidine triad;
PCNA 	 proliferation cell nuclear antigen.
Staining distribution (percentage positive cells): 0,  5% staining; 1, 6–25%;
2, 26–50%; 3, 51–75%; and 4, 76–100% (all reactions exhibited moderate
to strong staining intensity).
is found (LI: 4.1  2.7). The fluorescein labeling tends to be
relatively low at 3 d after BLM treatment, when only a few cells
are positive for SBs (Figure 6F; LI: 6.5  1.9), and absent at
5 d (Figure 6H; LI: 0.6 0.4). The DNASB labeling for NK1r/
mice at the various time intervals after BLM administration is
shown in Figures 6A, 6C, 6E, and 6G. No appreciable differences
in stain distribution (LI) and intensity are observed between
knockout and wild-type mice at 3 h (Figure 6A vs. 6B), 1 d
(Figure 6C vs. 6D) and 3 d (Figure 6E vs. 6F) after BLM.
However, several lung parenchymal cells of NK1r/ mice still
stain at 5 d after BLM administration (LI: 5.1  2.7), when a
negative fluorescein labeling is observed for wild-type mice
(Figure 6G vs. 6H). These data suggest that the loss function of
NK-1R does not influence the initial yield of DNA breaks in
response to BLM administration but does result in a delay of
DNA SB recovery.
Caspase-dependent Pathways Are Not Significantly Involved
in Cell Death after BLM Challenge
Caspase mRNA levels were assessed by RPA in lung tissue
from wild-type and NK1r/ mice at different times after BLM
administration. The most significant changes observed at the
different times are reported in Figure 6I. Wild-type mice do not
show significant changes in the expression of caspases 3, 7, and
8 in comparison with saline-treated control animals at 1 and
3 d after BLM challenge. Unlike wild-type mice, NK1r/ mice
show a significant enhanced expression of caspase 3 (233% in-
crease over control mice) at 1 d after BLM treatment (Figure
6K). In these animals, the expression of caspase 3 increases from
1 d up to 5 d after BLM challenge, reaching the most significant
difference from that of control mice at 3 d (466% increase). The
presence of active caspase 3 in lung tissue has also been analyzed
by Western blotting. Using an enhanced chemiluminescence
technique, we were unable to detect any trace of active caspase
3 in tissue samples of NK1r/ and wild-type mice at 1 and 5 d
after BLM administration (data not shown). By immunohisto-
chemistry, very few alveolar cells in alveolar septa of NK1r/
mice stained with anti–active caspase 3 antibody at various times
after BLM challenge (data not shown). The data obtained
strongly suggest that, at least at the dosage of BLM used by
us, the caspase-dependent pathways—whether mitochondrial-
dependent or receptor-mediated—are not significantly involved
in cell death after BLM treatment.
Nur77 and Some Members of the Bcl2 Family Are Implicated
in Cell Death after BLM Treatment: Requirement for
NK-1R Signaling
The role of nuclear orphan receptor Nur77/TR3 (Nur 77) and
of some members of the Bcl2 family in epithelial cell death in
response to BLM was investigated in wild-type and NK1r/
mice at various times after BLM administration. The lung histo-
chemical pattern of Nur77 in mice at 0 and 3 h and at 1 and
3 d after BLM challenge is reported in Figure 7. Under normal
conditions, Nur77 protein is not stained in bronchiolar and epi-
thelial lung cells of either genetically engineered or wild-type
mice (Figures 7A and 7B). This protein is highly labeled in the
cytoplasm of the lower airways and alveolar cells of wild-type
mice at 3 h (Figure 7D), 1 d (Figure 7F), and 3 d (Figure 7H)
after BLM treatment, but it is absent from lung sections of
NK1r/mice at the same time points (Figures 7C, 7E, and 7G).
It has been suggested that in response to specific cell death
stimuli, including NK-1R signaling (11), Nur77 translocates from
the nucleus to the cytoplasm, targeting mitochondria and induc-
ing cytochrome c release (28). In the cytoplasm, Nur77 binds
Bcl-2, which subsequently undergoes a conformational change
leading to exposure of its BH3 death domain (29). We therefore
examined the mRNA expression profile of Bcl2 and other Bcl-2
family members involved in apoptosis by RPA at various times
after BLM administration (Figure 7I). A significant increase in
the expression of Bak (a proapoptotic Bcl2 family member) and
other members with buried BH3 domains (i.e., BclXL, Bcl-2,
and BFL1) (30), which can undergo conformational changes
after Nur77 binding, is observed in wild-type mice at 3 d after
BLM. On the other hand, the only change seen in NK1r/mice
is an up-regulated expression of BclXL, which usually serves as
antiapoptotic molecule in absence of Nur77 (Figure 7I). These
data collectively suggest that at least under our experimental
conditions Nur77 and some members of the Bcl2 family are
implicated in cell death after BLM treatment, and that NK-1R
signaling is necessary for the translocation of Nur77 into the
cytoplasm and for the expression of some Bcl2 family members
involved in apoptosis.
DISCUSSION
In mice, the loss of function of the NK-1R induced either by
pharmacologic or genetic manipulation results in the development
of AC after BLM administration. The lung tumors are multicen-
tric, well-differentiated ACs, similar to well-differentiated human
ACs (24, 25), but without mucin production and desmoplasia.
Analogous to the adenoma–adenocarcinoma sequence in the
colon, it has been proposed that AC in humans arises from AH,
which progresses through AAH to AC (26). However, the data
supporting this sequence in the lung are largely circumstantial
and are mainly based on the association of these changes in
autopsy studies (31, 32). In our animals, a series of precursor
lesions characterize the development of AC. In particular, by
studying NK1r/ mice at various times after BLM administra-
tion, we observed (1) several foci of AH in otherwise normal
lung parenchyma at 7 and 14 d, (2) a predominance of areas of
AAH at 14 to 21 d, and (3) areas of AC sometimes contiguous
to foci of AAH from 21 d onwards. We were also able to demon-
strate small foci of cuboidal cell hyperplasia at 5 to 7 d after
BLM administration and before the occurrence of AH.
The presence of cell population resembling Clara cells within
the papillary areas of AC suggested the Clara cell as the cell
of origin of these tumors. However, the immunohistochemical
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Figure 6. DNA strand-break
(SB) extremities labeling and
caspase mRNA levels on lung
tissues from wild-type and
NK1r/ Balb/c mice after
bleomycin (BLM) treatment. (A,
C, E, G) DNA SB extremities
labeling from lung sections of
NK1r/ mice at 3 h (A ) and at
1 (C ), 3 (E ), and 5 (G ) d after
BLM. (B, D, F, H) DNA SB ex-
tremities labeling from lung
sections of wild-type mice at
3 h (B ) and at 1 (D ), 3 (F ), and
5 (H ) d after BLM. (I ) RNase
protection assay (RPA) for cas-
pases after BLM treatment. The
data in the graph are mean
values  SD obtained from
three different experiments
performed on different pools of
three lungs obtained at the
various times from wild-type
and NK1r/ Balb/c mice. The
gel electrophoretic autoradio-
graphs (I, top) were quantified
by Sigma gel analysis software
and the values of L 32 were
used to normalize the amounts
of RNA present in the samples.
*p 
 0.05.
analysis performed by using antibodies against CCSP and pro–
surfactant protein C, which are specific markers for Clara and
alveolar type II cells respectively, suggests that AC in our mice
is of alveolar origin. This conclusion is also supported by the
fact that the development of AC is preceded by a series of
morphologic lesions bearing cells that stain very strongly for
pro–surfactant protein C and are negative for CCSP. Moreover,
the absence in these cells of a dual expression of pro–surfactant
protein C and CCSP seems to exclude a role for a recently
identified bronchioalveolar stem cell as the cell of origin of our
neoplasm. This stem cell has been demonstrated to have a role
in murine lung epithelial neoplasms that develop in conditional
K-Ras mutant mice (16).
Several alterations in gene expression were found to be asso-
ciated with malignant transformation during the AH to AC
sequence in our mice. These alterations are sequential, and their
frequency and number increase or decrease with atypia during
the AH to AC sequence. In particular, staining for proliferation
cell nuclear antigen marker and Ki-67 proliferation marker in-
creases with increasing atypia when a decrease of the tumor
suppressor factor FHIT is demonstrated. The latter factor has
been involved in tumor initiation and progression of several
cancers including those of the lung (33). In addition, the progres-
sive accumulation of p53 expression does not parallel the expres-
sion of another member of the p53 signaling pathway, namely
p21. This means that the correlation between p53 and p21 (34)
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Figure 7. Immunohistochemis-
try of nuclear orphan receptor
Nur77/TR3 (Nur77) and RPA
for Bcl2 family members in the
lung tissue from wild-type and
NK1r/ Balb/c mice at various
times after BLM treatment. (A,
C, E, G) Immunostaining for
Nur77 in lung sections of
NK1r/ mice at 0 (A ) and 3 h
(C ) and 1 d (E ) and 3 d (G )
after BLM. (B, D, F, H) Immuno-
staining for Nur77 in lung sec-
tions of wild-type mice at 0 h
(B ) and 3 h (D ) and 1 d (F ) and
3 d (H ) after BLM. (I ) RPA for
Bcl2 family members after BLM
treatment. The data are mean
values  SD obtained from
three different experiments
performed ondifferent pools of
three lungs obtained at the var-
ious times from wild-type and
NK1r/ mice. The gel electro-
phoretic autoradiographs were
quantified by Sigma gel analy-
sis software and the values of L
32 were used to normalize the
amounts of RNA present in the
samples. BLM 	 bleomycin;
RPA 	 ribonuclease protection
assay. bad 	 *p 
 0.05.
is lost during the AH to AC sequence and that p21 expression,
which plays an important role in cell cycle regulation, becomes
independent during an early stage of transformation. Although
p53–p21 uncoupling is extremely frequent and unspecific be-
cause p21 may be a target gene of many other factors (e.g.,
p14ARF and FHIT), it is important to stress that p53–p21 uncou-
pling has also been reported to characterize the development
of the human lung AC (34). The data reported here suggest that
hyperproliferation and loss of cell cycle control are early events
in malignant transformation in our model ofAH toAC sequence
and that a series of alterations in gene expression characterizes
the sequence of the histopathologic changes that precede AC
development. These alterations can be considered indicative of
the preneoplastic nature of these lesions (35, 36).
Because mice carrying a targeted knock out of NK-1R do
not develop spontaneous tumors and in particular lung ACs
during their life, we concluded that NK-1R blockade alone can-
not cause neoplastic transformation and hypothesized that a
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“secondary” event, namely the BLM-induced DNA damage, is
necessary for tumor development and progression. BLM is a
radiomimetic anticancer drug that may produce many types of
DNA damage including single-strand breaks (SSBs), double-
strand breaks (DSBs), base damage, and DNA–DNA or DNA–
protein cross-links (37). Depending on the drug concentration
reached in the cell, BLM can induce different types of DNA
breaks (SSBs or DSBs) in the injured tissues (38). These changes
undergo repair or can induce cell death by caspase-dependent
(SSB) or caspase-independent (DSB) apoptosis pathways (39).
Low concentrations of BLM in the cell generally induce SSBs,
whereas high concentrations result in a high prevalence of DSBs
(38). Thus, under in vivo conditions, the prevalence of these
changes may vary on the basis of the dose of BLM used and
the route of administration.
Of the various forms of damage that are inflicted by BLM,
probably the most dangerous is the DSB. Inaccurate repair or
lack of repair of a DSB can lead to mutations or to a larger
scale genomic instability through the generation of dicentric or
acentric chromosomal fragments. Such genomic changes may
have tumorigenic potential (39). Thus, DSBs are potent inducers
of mutations and of cell death. However, the intracellular cell
death pathways that are activated on direct exposure of BLM
to alveolar epithelial cells remain to be clarified.
To investigate the role of the NK-1R blockade on the devel-
opment ofAC, we studied the different kinetics in the generation
and disappearance of DNA breaks in wild-type and NK1r/
mice after BLM challenge. The loss of function of NK-1R does
not influence the initial yield of DNA breaks in response to
BLM administration but does result in a delay of DNA break
recovery. This led us to hypothesize that defects in cellular re-
sponse to DNA SBs (e.g., inappropriate DSB repair events,
difficulty of cells to undergo apoptosis/cell death, or both) that
are generally recognized as a frequent initiating event in carcino-
genesis (40, 41) could be favored by the NK-1R blockade.
Because the exact role of DNA breaks in the triggering of
cell death is far from being well established, we evaluated the
contribution of the caspase-dependent pathways, Nur77, and
some members of the Bcl2 family in the epithelial cell death in
response to BLM in both wild-type and NK1r/ mice.
NK-1R has recently been shown to be involved in an alterna-
tive, programmed cell death. NK-1R death signaling is depen-
dent on arrestin 2–mediated activation of MAPK phosphoryla-
tion cascade integrated by Raf-1–MEK2–ERK2, leading to the
phophorylation of Nur77, the downstream effector of ERK2
activation (11). Nur77 translocates from the nucleus to the mito-
chondria, to trigger cytochrome c release and apoptosis (28).
Recent evidence suggests that Nur77 targets mitochondria
through its interaction with Bcl-2. In particular, Bcl-2 containing
buried BH3 death domain may be converted from protector to
killer by interaction with Nur77 (29).
The data obtained from wild-type mice support the idea that,
at least under our experimental conditions, Nur77 and some
members of the Bcl2 family are key regulators of the cell death
pathway after BLM exposure in alveolar epithelial cells. On the
contrary, the caspase-dependent pathways (either mitochondrial-
dependent or receptor-mediated) are not significantly involved.
The NK-1R blockade seems to interfere with this caspase-
independent pathway of apoptosis by affecting both the translo-
cation of Nur77 into the cytoplasm and the expression of some
important Bcl2 family members. These data strongly suggest
that the delay of DNA break recovery seen in NK1r/ mice
after BLM challenge is due to ineffective activation of the non-
apoptotic cell death pathway that involves Nur 77 and some
Bcl2 family members such as Bcl2 and Bak (14). On the other
hand, we cannot exclude the possibility that the loss of NK-1R
results in a gain of function (i.e., changes in p53 or other impor-
tant transcription factors) that could confer a dominant negative
status inhibiting the activation of p21.
In conclusion, although much more work is necessary to clar-
ify the molecular mechanisms that lead to the development of
AC under our experimental conditions, the observations re-
ported in this study open the way to identifying the signaling
pathways crucial for AC and the molecular characteristics of the
precursor lesions. The almost impossible task of identifying these
lesions before resection rules out any longitudinal study in hu-
mans. Our animal model of AC may facilitate designing and
testing of new therapeutic interventions against peripheral hu-
manACs and provide new information on the biology ofAC and
on potential targets for detection and possibly even treatment.
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